The content on this site is intended for healthcare professionals only
Dr Yves Menu talks to ecancer about the RECIST system for evaluating the effectiveness of treatments at the 2012 ESMO meeting in Vienna.
RECIST measures tumours morphologically and makes a follow up after treatment to determine efficacy. This is an international standard in treatment as it provides simple indicators that are universally understood.
Filming supported by Amgen
MCED blood test demonstrates high specificity, strong predictive value, and increased early cancer detection
Expectations and priorities of older patients with cancer: the PRIORITY multicenter cohort study
ERBB2 amplifications across sex, race, and cancer types studied to guide HER2 therapies
Assessment of suicide risk in cancer patients
Cancer journeys: Research from India
Depression in cancer
Managing 'fear of recurrence' of cancer patients
Psychological issues in familial cancer
OncoAlert round up July 28th to August 3rd, 2023
